Loading TrenasCycles…
Peptides / GHRH analog
Egrifta
Tesamorelin is used to reduce deep belly fat in adults with HIV-related lipodystrophy. It boosts growth-hormone release rather than supplying growth hormone directly. It targets that specific fat problem without much change in total weight, so it is not a general cutting drug. Swelling, joint pain and higher blood sugar are the main drawbacks.
Egrifta WR for excess abdominal fat in adults with HIV-associated lipodystrophy. WR and SV formulations have different doses and are not interchangeable; this amount does not describe generic research tesamorelin.
Controlled trials and official labeling support its narrow HIV-lipodystrophy indication, not general fat loss, muscle gain or anti-aging use.
Increased IGF-1, fluid retention, joint symptoms, glucose intolerance or diabetes, injection reactions and contraindications related to malignancy and pregnancy; long-term cardiovascular safety is not established.
IGF-1, glucose status, edema and joint symptoms, injection sites and malignancy-related considerations under specialist care.
Approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. It is not indicated for general weight loss or bodybuilding.
Documents the approved indication, subcutaneous route, contraindications, warnings and monitoring for tesamorelin.
The label does not support general weight loss, anti-aging or bodybuilding use; long-term cardiovascular safety is not established.
Original source ↗